GPCR.US Structure Therapeutics Inc. American Depositary Shares

Healthcare Biotechnology USA Stocks
20.00 USD
Close of Nov 13, 2026
18.70 94.90
Market cap
USD 1.43B
P/E
-
P/B
1.15x
ROE
-35.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GPCR.US undervalued?

Graham number

The Graham number of Structure Therapeutics Inc. American Depositary Shares cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Structure Therapeutics Inc. American Depositary Shares fundamental analysis

No fundamental analysis for Structure Therapeutics Inc. American Depositary Shares yet.

Structure Therapeutics Inc. American Depositary Shares stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Structure Therapeutics Inc. American Depositary Shares

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-…

Full company profile